 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "Acetergamine" – news ·newspapers ·books ·scholar ·JSTOR(March 2024) |
 | |
| Names | |
|---|---|
| Systematic IUPAC name N-{[(8β)-6-Methylergolin-8-yl]methyl}acetamide | |
| Other names 8β-acetylaminomethyl-6-methylergoline (+)-N-Acetyl-9,10-dihydrolysergamine | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| ECHA InfoCard | 100.019.281 |
| UNII | |
| |
| |
| Properties | |
| C18H23N3O | |
| Molar mass | 297.402 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Acetergamine is anorganic chemical compound; specifically it is a derivative ofergoline, making it a member of theergotamine family of compounds. Acetergamine currently has no mainstream uses, however its potential as analpha-1 blocker andvasodilator has led to it being covered in several patents concerning therapies for erectile dysfunction. It has also been investigated as a treatment forcerebellar ataxia.[1]
